GPCR Therapeutics, Inc.
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | CXCR4Small molecule | Multiple Myeloma |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
8 December 2025Topline resultBurixafor (TG-0054)Phase 2 of burixafor with propranolol and G-CSF meets primary endpoint in multiple myeloma mobilization
Exicure, Inc. · Source ↗
Financial reports
No financial reports recorded.